Sitemap

Resources

• 10th AMR Conference 2026
• 10th RSC-BMCS Fragment-based Drug Discovery Meeting
• 12th International Congress on Biocatalysis (biocat2026)
• 14th Annual Texas Life Science Forum
• 14th Tumour Models London Summit 2025
• 16th Annual World ADC London 2026
• 19th WRIB 2025
• 1st RSC Protein and Peptide Science Group Conference
• 2 Analytical Platforms for Peptide Preclinical Testing: LC-MS & ELISA
• 2026 ADA 86th Scientific Sessions
• 2026 FENS Forum
• 20th Drug Discovery Strategic Summit
• 22nd RSC Nucleic Acids Forum 2026
• 24th San Diego BioPharma Conference
• 25th EuroQSAR
• 3 Benefits of In Vitro ADME Testing Automation
• 3 Common Missteps in Nonclinical Safety Assessment Testing
• 3 DMPK Strategies for ADC Drugs
• 3 Important DMPK Considerations for Successful Oligonucleotide Preclinical Testing
• 3 Important DMPK Considerations for Successful Peptide Preclinical Testing
• 3 Must-Have Qualities of a Bioanalytical Method Development & Validation Partner
• 3 Therapeutic Considerations for the Future of Oligonucleotide Development
• 37th BMCS Spring Symposium on Medicinal Chemistry
• 39th ACS National Medicinal Chemistry Symposium
• 3rd RNA Horizons Conference
• 4 Analytical Methods Commonly Used in Oligonucleotide Preclinical Testing
• 4 Critical In Vitro Genotoxicity Assays for Preclinical Drug Development
• 4 Essential Safety Assessments to Consider for Peptide Preclinical Testing
• 4 Reasons Non-GLP Bioanalysis Matters for DMPK Testing
• 4 Reasons Why Genetic Toxicology is Foundational to Modern Drug Development
• 5 Critical Nonclinical Toxicology Studies Required for IND Submission
• 5 questions drug developers need to ask when vetting laboratory testing partners
• 5 Questions When Planning a Nonclinical Toxicology Program for Biotherapeutics
• 5 Tips to Navigating Antisense Oligonucleotide Drug Development
• 5 Ways You Can Automate Preclinical Bioanalysis
• 5th Alpine Winter Conference on Medicinal and Synthetic Chemistry
• 6 Essential Qualities in a Drug Safety Assessment Testing Partner
• 6 Factors That Can Make or Break the mRNA Therapeutic Development
• 6 Key Challenges in Oligonucleotide Development & Testing (And How to Overcome Them)
• 6 Strategies to Overcome PROTACs' Developmental Challenges
• 6 Types of Toxicology Studies for IND & NDA Programs
• 6th Ace Drug Discovery Summit
• 6th Swiss Industrial Chemistry Symposium (SICS)
• 7 Common Bioanalytical Services Pitfalls That Delay IND Timelines
• 7 Most Common Bioanalytical Testing Platforms for Small and Large Molecule Bioanalysis
• 8th Targeted Protein Degradation Summit
• 9th Immunotherapies & Innovations for Infectious Diseases (I4ID) Congress
• A Celebration of Organic Chemistry
• A Guide to In Vitro ADME Testing in Drug Development
• A High-Sensitivity Stem-Loop RT-qPCR Method for RISC-Loaded siRNA Quantitation
• A New Development Playbook for PROTACs
• A New Method to Improve Identification of the Payload-Containing Catabolites of ADCs
• A New Oligo Playbook: Building a Tailored, Risk-Based Strategy to a Successful IND
• A New Playbook: 5 Ways to Improve Safety & Decision-Making With In Vitro Toxicology
• A Novel Derivatization Procedure for the Chemicals with Carboxylic Acid and Its Application in LC-MS/MS Bioanalysis
• A Novel Murine Model of MetALD for Therapeutic Drug Evaluation
• A Novel Preclinical Mouse Model of Neutrophilic Asthma
• A Novel RT-qPCR Methodology for Quantitative Bioanalysis of Total and Conjugated siRNA in Antibody-Oligonucleotide Conjugates (AOCs)
• A pharmacodynamic analysis platform for targeted protein degrader drugs
• A Quantitative Analysis Method for Intracellular Proteins
• A Retrospective Analysis of the Potential Associated Factors of Procedure-Related Findings in Intrathecal Injection Studies
• A Retrospective Study of Nonclinical Safety Data for siRNAs
• A Step Forward in Oligo Therapy: A New Assay for Testing Oligo Stability in Plasma
• A Step-By-Step Guide to Successful IND Studies
• A Strategic Roadmap for Peptide Preclinical Studies: 3 Key Stages
• AACR Annual Meeting 2026
• AAPS
• AAPS PharmSci 360 Annual Meeting 2025
• Accelerating Peptide and Oligonucleotide Development Through Integrated Preclinical Strategies
• ACT
• Acute Toxicity Studies: 3 Best Practices to Stay on Track with Your IND Timeline
• Acute Toxicity Studies: Best Practices for First-In-Human Readiness
• AD/PD 2026 Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
• ADCs and Ocular Toxicity: Mechanisms and Management
• ADDC 2025 Colloquium
• Addressing Ocular Safety Challenges In ADC Development
• Addressing pH-Dependent Lactone–Carboxylate Interconversion to Resolve Quantitation Bias in the Bioanalysis of Exatecan-Based ADCs
• Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
• Advanced Conjugate Delivery Systems for Oligonucleotides
• Advanced Screening Methods for Better Drug Targets
• Advances in Cell-Based Screening in Drug Discovery
• Advances in Covalent Drug Discovery Technologies
• Advancing Conjugated Therapeutics: From ADC Innovation to Integrated Bioanalysis Strategies
• Advancing In Vitro Metabolic Models and Metabolite Identification for Oligonucleotide Therapeutics
• Advancing Metabolic Disease Drug Development
• Advancing Novel Therapeutics with Innovative DMPK Strategies in Metabolism and Bioanalysis
• Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage
• Advancing Preclinical Bioanalytical Strategies for GLP-1 Receptor Agonists
• Advancing Preclinical Bioanalytical Strategies for Today’s Diverse Vaccine Platforms
• Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B
• Alzheimer’s Disease Biomarkers: Toward More Precise Testing
• American Heart Association (AHA) Scientific Sessions 2025
• An ADME Guide for Successful siRNA Therapeutics: Insights from Approved Drugs
• Analyzing FDA guidance on DDI studies for therapeutic proteins
• Anglonordic Life Science Conference XXII
• Animal Disease Models in Ocular Drug Development
• Antibody Drug Conjugate Services: Overcoming Bioanalysis Challenges
• Antibody-Drug Conjugate
• Antibody-Drug Conjugate Bioanalysis
• Antibody-Drug Conjugates (ADCs): Potent Cancer Killers with PK Challenges
• Antibody-Targeted Precision Medicines
• Anticipating IND submission: Ensuring your drug is ready for preclinical toxicology studies
• Antisense oligonucleotides: Navigating ethical and safety challenges
• AOCs Explained: Delivery, DMPK, and the Future of Antibody Oligonucleotide Conjugates
• Application of Lecithin (PL90) and Poloxamer 188 in Permeability and P-GP BCRP Mediated Drug Interaction Studies in Caco-2 Cells
• Application of Lecithin (PL90) and Poloxamer 188 in SLC Transporter-Mediated Drug Interaction Studies
• Application of Protein Biomarkers in Pharmaceutical Research and Bioanalysis Strategies
• Application of qPCR Technology in the Bioanalysis of Oligonucleotide Drugs
• BAS Global Central Laboratories
• Basic Questions Developers Are Asking About In Vitro-In Vivo Extrapolation
• Bavarian Tradition Meets Biotech
• Better In Vivo Model Welfare, Better Data: A Preclinical Playbook
• Beyond chemotherapy: The rise of precision medicine with radionuclide drug conjugates
• Beyond GLP-1: Preclinical hurdles and solutions for next-generation peptide therapeutics
• Beyond Single-Marker Pathology: How Highly Multiplex Fluorescence Imaging Is Expanding Translational Research
• Beyond Targeting: How ADC Payloads Drive Toxicity and IND Risk
• Beyond the Magic Bullet: Innovations in ADC Design and Nonclinical Safety Strategy—A Q&A with Sue McPherson
• BIA Summer Party 2026
• BIO EU Spring
• BIO Europe
• BIO-Europe 2025
• Bio-Neuroscience 2026
• bio:cap Life Science & AI Investival
• Bio€quity Europe 2026
• Bioanalysis Considerations for CAR T-Cell Therapies
• Bioanalysis in the Age of New Drug Modalities
• Bioanalysis of ADC Drugs by LC-MS/MS
• Bioanalysis of GLP-1 Antagonist Drugs by Multiple Analytical Platforms
• Bioanalytical Applications of ICP-MS
• Bioanalytical Challenges and Strategies of T-cell Engager Therapeutics
• Bioanalytical method development and validation using Quanterix’s Simoa platform
• Bioanalytical Method Development and Validation: What IND Sponsors Need to Know
• Bioanalytical Services
• Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies
• Bioanalytical Strategies for Fusion Proteins
• Bioanalytical Strategies for Peptide-Drug Conjugates (PDCs): Optimized Approaches for the Pharmaceutical Industry
• BioBeat 2026: Insight, Perspective, Connection
• Biocom California Global Life Science
• BioFIT 2025
• Biological Significance and Bioanalytical Strategies of Biomarkers – Complement Detection
• Biomarker Assays in Drug Development: Choosing the Right Platform
• Biomarker Assays: Designing Assays That Scale from Preclinical to Clinic
• Bionow Neuroscience Conference 2026
• Biophysical Methods for Rapid Screening and Hit Validation
• bioRN Events & Lounge
• BioSeed 2026
• BIOSPAIN 2026
• Biotech Booster Annual Event 2026
• Biotech Showcase 2025: Interview with Dr. Steve Yang, co-CEO of WuXi AppTec
• BioTrinity 2026
• BioVaria
• Bispecific antibodies: The next generation of precision therapeutics
• Bispecific/Multispecific Antibodies
• BMCS 3rd Conformational Design in Drug Discovery 2026
• BOS Manchester 2025
• Boulder Peptide Symposium 2026
• Bridging bioanalytical gaps: Examining validation methods across species
• Bridging bioanalytical gaps: Examining validation methods across species
• Bringing Biology and Testing Expertise Together Online
• Cancer Pharmacology Services
• Cancer Pharmacology Services
• Case Study-Strategy of Follow-up Assays in Genotoxicity
• CEBioForum 2026
• Central Nervous System (CNS) Drugs
• Challenges and solutions in bioanalysis for oligonucleotide drugs
• Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
• Chemical Biology meets Drug Discovery 2026
• Clinical Analysis Strategies for Complement Biomarkers
• Clinical Bioanalysis Strategy for Antibody Drug Conjugates (ADCs)
• Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment
• Combining Immunocapture and Microflow Liquid Chromatography-Tandem Mass Spectrometry to Advance Bioanalysis of Protein Biomarkers in Toxicological Studies
• Comparison of Different Assay Kits for Dog Serum PTH Measurement
• Comparison of Ocular Features in Bama and Göttingen Minipigs
• Comparison of Systemic Exposure in Pregnant and Non-Pregnant Sprague-Dawley Rats
• Comprehensive Bioanalysis of ADCs in DMPK Studies
• Controlling Risk in High-Throughput Bioanalysis
• Cost-effective In Vitro Methods for Evaluating the DDI Potential in Drug Discovery
• Covalent Modulation In Drug Discovery
• CPHI Frankfurt
• Crelux Introduces its New Location in Munich-Gräfelfing
• CTHRC1 as a Novel Candidate for Neurodevelopmental Disorders
• Custom Care: Bioanalysis and the Future of Personalized Medicine
• Cytokine Profiling for Immunotoxicity Assessment: Comparison of MSD®, Luminex®, and CBA Multiplex Platforms in Preclinical Matrices
• D2B: Direct-to-Biology Platform
• DAR Research on ADCs Using LC-MS
• DDI Marbach Workshop
• DDI Marbach Workshop
• De-Risk Your IND and NDA: Avoid These 5 DART Pitfalls
• De-Risking mRNA-LNP Therapeutics Through Integrated DMPK, Bioanalysis and Toxicology
• Decoding Complex Metabolite Related Drug-Drug Interactions
• DEL and Display Technologies Empower Discovery of Peptide Drugs
• DEL SE 2.0: WuXi Biology Launches Upgraded Edition of DNA-Encoded Library Kit
• Designing Juvenile Toxicology Studies: Key Considerations for Drug Development
• Desorption Strategies in Peptide Formulation Preparation Insights from In Vitro Adsorption (Non-Specific Binding) Assessment Experiments
• Detect and Characterize In Vitro PCCs of Non-Cleavable ADCs Using a New LC-HRMS Method
• Developing a Convenient In Vitro Method for Predicting Metabolism and Disposition of Acrylamide Covalent Drugs in Humans
• Development and Implementation of a Ferret Venous Catheterization Model for Pharmacokinetic Studies
• Development of in vitro Methods to Assess Inhibition Potential in Nine Recombinant UGT Isozymes
• Development of the Venetoclax-Resistant AML Model
• Development, Comparison of Quantitative Analytical Methods to Evaluate Plasma Antibody-Drug-Conjugates
• Discovery & Development Europe 2026
• Discovery on Target 2026
• Diurnal Variations Analysis of the Cardiovascular Parameters in Cynomolgus Monkeys of Stand-Alone Safety Pharmacology Studies
• DLL3‑related Tumor Models in Humanized Mice
• DMDG - EU
• DMDG Meeting
• DMPK Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
• DMPK Challenges and Strategies for Developing Oligonucleotide Drugs
• DMPK Drug Metabolism and Pharmacokinetics Catalog
• DMPK Optimization of Proteolysis-Targeting Chimeras
• DMPK Strategies for Advancing Preclinical Development of AOC Therapeutics
• DMPK Strategies for Oligonucleotide Therapeutics
• DMPK Strategies for Proteolysis-Targeting Chimeras: Addressing ADME and PK Challenges
• DMPK Strategies for Successful Clinical Translation
• DMPK Strategies in the Preclinical Development of Antibody-Drug Conjugates
• Dose Range-Finding Studies for Safety Assessment: 3 Reasons Not to Skip Them
• Drug Discovery 2026
• Drug Discovery Chemistry
• Drug Discovery Masterclass for Academics
• Drug Solubility Testing: 4 Ways It Helps Drug Discovery & Development
• Drug-Drug Interaction: An Overview of Inhibitors
• Drug-Drug Interaction: An Overview of Substrates and Metabolizing Enzymes
• Drug-Resistant KRAS G12D Lung Cancer Models
• EANM'26 Annual Congress - European Association of Nuclear Medicine
• Early ADME Screening: 3 Ways It Boosts IND Submission Success
• Early siRNA Formulation Screening Using Lumbar Intrathecal Infusion via Cannulation vs. Free-Hand Method – A Comparison for Preliminary Toxicity Detection Using Behavioral Tests and Tissue Distributions
• Early-Stage Considerations for Optimizing Respiratory Drug Development
• Early-Stage Considerations for PROTAC Development: From Design to Preclinical Readiness
• Early-Stage PROTAC Development and the Road to IND
• Effect of Bovine Serum Albumin on Permeability, Efflux Ratio and Recovery of Compounds in MDCKII-MDR1 Monolayers
• Efficacy of a Cell Therapy Drug on Kainic Acid-Induced Seizures
• Efficacy of a TL1A Antibody in an Acute Colitis Mouse Model
• Efficacy of Biologics in Humanized Mouse Models for IBD
• Efficacy of Xanomeline on Cognitive Dysfunction
• EFMC International Symposium on Medicinal Chemistry
• EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026
• ELISA v LC-MS/MS: Preclinical Bioanalysis Platforms for ADCs in Focus
• ELISpot Assays: The Key to Unlocking Advanced Cellular Immunity Testing
• ELRIG Women’s Health Forum
• Embracing the Future: How In Vitro Assays Are Transforming Nonclinical Toxicology
• End-to-End CRDMO Platform for Oligonucleotide Drugs
• Enhancing Oral Bioavailability in Preclinical Dog PK Studies Using Ball Milling Technology
• Enhancing Treatment of MASH with Combination Therapies
• Ensuring Multi-Ion Channel Inhibition Assays are Accurate and Reliable
• EpCAM-CD3 BsAb-Encoding mRNA Suppresses Lung Tumors
• Establishing Reference Ranges for Lymphocyte Subsets in Healthy Bama Minipigs for Immunotoxicity Assessment
• Establishing the Internal hERG Safety Margin Threshold Using a Series of Reference Drugs to Support the Integrated QTc Risk Assessment
• Establishing the Preclinical Immunotoxicity Reference Based on Immunophenotyping Data in Bama Minipigs
• Establishment of a High-Throughput Screening and Characterization Platform for Covalent Inhibitor Drugs
• Establishment of a Novel Funnel Model for Evaluating Blood-Brain Barrier Penetration in Vitro
• Establishment of a Quantitative Analytical Method for Albumin-Drug Conjugates in Rat Plasma using Ultra-high Performance Liquid Chromatography-Tandem Mass Spectrometry
• EU New Drug Applications: 5 Tips to Prepare for Scientific Advice Requests
• Eurobiomed Annual Meeting
• European Bioanalysis Forum (EBF) Open Symposium
• European ISSX
• EUROTOX
• EUROTOX
• Evaluating Off-Targets of siRNA Drugs
• Evaluation of Immunogenicity for Oligonucleotide Drugs
• Evaluation of the Impact of the Use of Slide Imaging in the Histopathological Evaluation of Toxicology Studies
• Evaluations of Targeted Delivery Systems for RNA Therapeutics
• Everything Drug Developers Need to Know to Prepare for IND Submissions
• Evolution of AAV Therapy: Challenges, Breakthroughs, and Future Directions
• Examining the dominant bioanalytical methods for Oligo development
• Exclusive Interview with Genetic Engineering & Biotechnology News
• Exclusive Interview: 25th Anniversary
• Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines
• Exploring Cremophor-Induced Allergic Reactions In Beagle Dogs Mitigation Strategies For Injectable Formulations
• Exploring future cancer therapies: Designing linkers to increase ADC efficacy and reduce toxicity
• Exploring Oligonucleotide Drugs: An Overview of Pharmacokinetic & Bioanalytical Strategies
• Facilitating ADC Preclinical DMPK Research with An Integrated Bioanalysis Platform
• Fast Biomimetic High-Performance Liquid Chromatography Method for Evaluating Human Plasma Protein Binding
• Featured Interview: Scaling Success
• Featured Interview: The End of the Undruggable
• Festival of Biologics 2026
• Finding the Best Lab Partner for your IND Submission
• Five Keys to Success in Bispecific Antibody Development
• Five Pointers to Successfully Navigate the Challenges of Peptide Therapeutic Development
• Five Tips for Toxicology and Emerging Modalities | WuXi AppTec
• Five Tips to Tackle the Bioanalytical and PK Challenges of ADC Development
• Five Ways LNP-mRNA is Shaping the Future of Medicine
• Five Ways PROTACs Break From ADME Norms
• Five Ways to Accelerate Peptide and Oligonucleotide Development Through Integrated Toxicology Studies
• Five Ways to Ensure hERG Assays are Scientifically Reliable
• Flanders-UK Immunology and Immunotherapy Partnering Forum 2026
• Flexibility as a Core IND Strategy
• Flow Cytometry Bioanalysis
• Flux Dialysis: A Cutting-Edge Tool for PPB Studies & Understanding DDI
• Four Essential Pointers to Navigate CNS Regulations and Safety Assessments
• Four Tips to Help Unlock Oligonucleotide Therapies for the Central Nervous System
• Four Tips to Optimize Transdermal Drug Delivery
• Four Ways to Unlock the Potential of Antisense Oligonucleotides in Eye Care
• From 40 Billion Molecules to Druggable Potential
• From Bottleneck to Accelerator: How Strategic DART Study Designs Can Speed IND Acceptance
• From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling
• From Concept to Market: The Strategic Journey from IND to NDA
• From Discovery to IND: A Biology-First Approach to New Modalities:
• From Hit Identification to IND: Building a Tiered DMPK Strategy for Drug Development
• From IND to Clinic: Lab Testing Milestones in Early Clinical Trials
• From Molecule to IND: A Strategic Roadmap Through Preclinical Studies
• From Preclinical Toxicology to Clinical Safety: The Path for Oncology IND Submissions
• From screening to IND submission: Biomarker analysis in preclinical drug development
• Fully Automated HTS Platform for Screening Diverse Targets
• Fusion Protein & Peptide-Drug Conjugate (PDC)
• German Biotech Days
• Global Health Exhibition
• GLP vs. Non-GLP Tox: Choosing the Right Study Design
• GLP vs. Non-GLP toxicology studies: When to use which guidelines?
• GLP-1 Bioanalysis
• GLP1R and GIPR Dual-Target Drugs in Humanized GIPR Mice
• Guidance Updated by U.S. FDA for Safety Testing of Drug Metabolites
• High-throughput FAMA Assay to Measure Humoral Immunity against Varicella-Zoster Virus
• Hot Topics and Challenges in Drug Development
• How a New Rapid EMSA Method is Impacting Plasma Protein Binding in Oligonucleotides
• How Animal Welfare Bolsters Research Reliability
• How AOCs are advancing targeted therapeutics
• How Bioanalytical Laboratory Automation Improves Timelines and Accuracy
• How Bioanalytical Laboratory Services Reduce Risk in Preclinical Programs
• How Biomarker Testing Services Support Precision Medicine Programs
• How DMPK Lead Optimization Mitigates Risk and Conserves Resources
• How Early Safety Pharmacology Studies Accelerate Drug Development and Reduce Risk
• How lab automation reinforces regulatory compliance for bioanalytical method validation
• How MetID studies can improve safety and efficacy in PROTAC drugs
• How Radionuclide Drug Conjugates are Transforming Cancer Treatment
• How to Accelerate the Synthesis of PROTACs: Strategies and Case Studies
• How to Address Metabolite Identification Challenges in Advanced Peptide Therapeutics
• How to Evaluate the Preclinical Safety of Oligonucleotide Drugs
• How to Improve PROTACs’ Oral Bioavailability
• How to Overcome 9 Key Peptide Drug Development Challenges
• How to Tackle the Developmental Challenges of PROTAC Drugs
• How to tackle the unique pharmacokinetic properties of covalent drugs
• How to Validate Whole Slide Imaging for Toxicological Pathology
• How WuXi AppTec’s San Diego Site Connects Biology and Chemistry
• HPV18 Tumor Models for Cancer Vaccines and Immunotherapy
• HTS Platform to Advance Molecular Glue Discovery
• Human Pharmacokinetics Prediction for Trastuzumab Using Scaling and Two-Compartment Modeling with B-hFcRn Mice PK Data
• Hybrid-ELISA in the Bioanalysis of Oligonucleotide Drugs
• ICAR 2026 - International Conference on Antiviral Research
• ICH M10: What the Finalized Guideline Means for Bioanalytical Scientists
• Immunotoxicity reconsidered: adapting preclinical strategies for emerging therapies
• Improving Bioanalytical Flexibility and Efficiency with Whole Blood Cryopreservation
• Improving Preclinical Outcomes: De-Risking Your Drug Development Program
• Improving PROTAC Drugs with MetID Studies
• Improving Submission Quality: Preparing For Regulatory Differences
• In Vitro ADME Testing: When It’s Enough – and When It’s Not
• In Vitro and In Vivo Efficacy of CAR-T Delivery
• In Vitro DDI Considerations for New Modalities
• In Vitro Metabolic Stability Evaluation of Peptides
• In Vivo ADME Testing in Drug Development: A Short Guide
• In Vivo CAR-T Preclinical Evaluation Platform
• In Vivo CAR-T: An Integrated Framework
• In Vivo Evaluation of VEGF-Targeted Bispecific Antibodies
• IND Application Essentials: What Data Regulators Actually Scrutinize
• IND Studies: Understanding Early-Stage Regulatory Needs
• IND Submission Strategy: Common Gaps That Delay First-in-Human Studies
• IND-Enabling Studies: How to Integrate ADME, Bioanalysis, and Tox for a Successful IND
• IND-Ready Immunotoxicity: Four Decisions to Prevent Late Surprises
• IND, Enabled
• Induced Pruritus Model in NHP
• Influence of ssDNA or dsDNA Tags on Ligand Binding Affinity
• Innovating bioanalysis to advance oligonucleotide therapeutics
• Innovations in Drug Development: The Increased Utility of In Vitro Testing
• Innovative Bioanalytical Strategies for Oligonucleotide Therapeutics: A New Frontier in American Drug Development
• Innovative direct delivery strategies to unlock oligonucleotide therapeutics for CNS disorders
• Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates
• Integrated bioanalysis strategies in nonclinical early in-vivo PK studies of siRNAs
• Integrated bioanalytical strategy for LNP-mRNA products
• Integrated Direct-to-Biology (D2B) Platform
• Integrated Platform Supporting ASO Drug Discovery
• Integrated Strategies for Advancing CNS Drug Development
• Integrated Strategies for KRAS Inhibitor Development
• Integrative Approaches to Toxicology for Emerging Modalities eBook’s
• International ISSX Meeting
• International Oligo & Peptide Conference (IOPC)
• Intrathecal Administration Techniques for CNS Delivery in Non-Human Primates Practical Tools for Oligonucleotide Drug Pharmacokinetics
• Investigation of Embryo-Fetal Development Toxicity of Cyclophosphamide in Mice
• Investival Showcase
• Is the Direct or Indirect Method the Ideal One for Evaluation of Blood to Plasma Ratio
• Is Your Drug Ready for Preclinical Toxicological Testing?
• ISSX
• Key Challenges in Oligonucleotide Bioanalysis—And How to Overcome Them
• Key Components of IND Study Strategy Planning
• Key Safety Considerations During Oligonucleotide Development
• Key toxicology considerations for large molecule therapies
• Key Toxicology Considerations for Large-Molecule Therapies
• Knowledge for Growth
• KRAS G12D Inhibitor-induced Resistant Tumor Models
• Large Molecule Bioanalysis
• LC-MS Bioanalysis of Oligonucleotides
• LCMS Preclinical Bioanalysis of LNPs in Advanced Therapy Drugs
• Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy
• Life – the biomedical convention 2026
• Liquid Chromatography-Tandem Mass Spectrometry Based Bioanalytical Strategies for Lipid-Oligonucleotide Conjugates
• Making the Most of the Golden Age of Small-Molecule Oncology Drugs
• Managing critical reagents through drug development
• Managing Critical Reagents: An Essential Part of Your Bioanalytical Strategy
• Mapping the Next Phase of Analytical Innovation for ADCs
• Mass Spectrometry-based Bioanalysis Platform
• Maximizing Outcomes Through Multi-Site Study Collaboration
• Maximum Tolerated Dose (MTD): How Dose-Range Finding Drives IND Success
• Measurement of Phosphoinositide (PIP) Metabolism via Derivatization-Based Liquid Chromatography-Tandem Mass Spectrometry
• Mechanism-Based Large Animal PK Strategies to Accelerate Oral Peptide Development
• Mechanistic Profiling of ADC-resistant Cancer Cell Lines
• Meet2Win 2026
• Metabolic Stability in Drug Development: 5 Assays
• Metabolic stability: The defining challenge for multifunctional peptides
• Method Development and Optimization for Intrathecal Injection in Dogs
• Method Qualification for Immunophenotyping of CD137+ T Cell Subsets
• Method Validation for the Reactive Oxygen Species (ROS) Assay for Photoreactivity
• Method Validation of Classical and Alternative Pathway Complement Activity
• Microsymposium on RNA Biology
• Modernizing Safety: The Predictive Power of In Vitro Toxicology
• Moving From GLP-1 to Multi-Target Metabolic Medicines
• mRNA Analytical Services: What Makes Testing Fit-for-Purpose
• mRNA Drugs: Progress, Production, and Prospects
• mRNA Vaccines and Therapeutics Conference
• mRNA-Based Therapeutics Bioanalysis
• mTOR Inhibition Enhances Targeted Protein Degradation Efficacy
• Munich Lab Automation Community (MLabAC) Meetup
• NAMs in Focus: The Evolution of Skin Irritation and Corrosion Testing Based on Reconstructed Human Epidermis Models
• NAMs: Defined Approaches for Skin Sensitization Studies
• Navigating 505(b)(1), 505(b)(2) and 505(j) Drug Approval Pathways
• Navigating evolving clinical and regulatory expectations as mRNA outgrows its vaccine roots
• Navigating the ADC Development Pathway
• Navigating the Complexities of Ocular Drug Delivery Systems
• Navigating the Path from IND to NDA
• Nervous System (CNS) Drug Delivery Techniques in Large Animals (Non-Rodents) Enhancing DMPK Research for Oligonucleotide Drugs
• Neuroscience 2025
• New approaches to the treatment of Parkinson’s
• Non-Drug Induced Spontaneous Convulsions in Different Nonclinical Laboratory Animals Used for Non-Clinical Drug Safety Evaluation
• Nonclinical Safety Evaluations of ADC Drugs
• Nordic Life Science Days
• Nordic Life Science Days 2026
• Normal, But Not Normal, Review of Some Vehicle-Related Histopathology Findings in the Concurrent Control Animals in the General Toxicity Studies Poster
• Not All Literature-Based Structural Alerts Lead to Mutagenicity
• Novel E3 Ligase to Support Targeted Protein Degradation
• Novel Rat Intrathecal Catheterization Model for Direct Antisense Oligonucleotide (ASO) Drug Delivery to the Central Nervous System
• Obesity Week
• Oligonucleotide Development: History, Pain Points & Bioanalytical Considerations
• Oligonucleotide Discovery Services
• Oligonucleotide DMPK Research Strategy & In Vitro Metabolism Models
• Oligonucleotide Drugs
• Oligonucleotides for CNS Summit
• Oligos for Ocular Diseases: Overcoming the Challenges
• Oncolytic Virus Therapies: Key Considerations for Clinical Bioanalysis
• OncoWuXi 3.0: A New Upgrade Empowering Drug Development
• OncoWuXi's New Antibody Library Launch: An Innovative Step Forward in Drug Development
• Ophthalmology Services Brochure
• Optimising analytical strategies for ADC development
• Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1α
• Optimizing ADC Bioassays: LC-MS/MS Blends Speed with Cost-Effectiveness
• Optimizing DART Assessments for Regulatory Success & Emerging Modalities
• Optimizing DMPK Strategy for Peptide Drugs
• Optimizing Safety in ADCs and RNA-Based Therapies Using MTD Testing
• Overcoming Challenges for Preclinical Bioanalysis of ADC Therapeutics
• Overcoming Challenges in Ocular Drug Testing with Advanced PK/PD Approaches
• Overcoming Challenges in Precise Structural Identification of Target Metabolites
• Overcoming challenges when developing oligonnucleotides for opthalmic drugs
• Overcoming nonspecific binding challenges in PK assays
• Overcoming Osteoporosis R&D Bottlenecks
• Overcoming the challenges of metabolite identification and profiling for developing oligonucleotides
• Overcoming the challenges of preclinical evaluations for PROTACs
• Panel Discussion: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
• Pathologists Can Move Your Drug Development Program Forward
• Peptide Development: A Tiered DMPK Approach to Bridge Discovery and IND-enabling Studies
• Peptide Drug Conjugates: Analytical and PK Considerations
• Peptide Drugs
• Peptide Early Discovery Services
• Peptide Therapeutics Forum
• Peptide Therapeutics: Navigating Development with DMPK & Toxicology
• Peptide-Drug Conjugate
• Peptides in practice: what it takes to advance these therapies to clinic
• Pharmacokinetic Bioanalysis Strategies for Antibody-Drug Conjugates (ADCs) Based on LC-MS
• Pharmacokinetic Comparison of Pemetrexed Administered via Lumbar Intrathecal vs. Cisterna Magna Intubation in Sprague-Dawley Rats
• Pharmacology 2025
• PK Study Design: Avoiding Rework in Early Pharmacokinetics
• Poster: Defining the Next Era of Cancer Therapeutics
• Preclinical Drug Development Demystified: Your ADME to Toxicology Roadmap
• Preclinical Oligonucleotide Drug Development: Insight from DMPK
• Preclinical vs. Clinical Biomarkers: Differences That Matter
• Preparing an IND submission: Here is what drug sponsors should anticipate
• Preparing Drug Developers for Developmental and Reproductive (DART) Studies
• Preparing for Preclinical Testing: A Readiness Checklist
• Presentation: Defining the Next Era of Cancer Therapeutics
• Probing Drug and Metabolite Covalent Binding with a Non-Radiolabeled Method Osimertinib as an Example
• Progress and Challenges in Tumor Vaccine Development
• Propylene Glycol Dose-Dependent Hemolysis in Intravenous Formulations Thresholds and Mitigation Strategies in Beagle Dogs
• PROTAC Services: Navigating DMPK and Bioanalytical Complexities
• PROTACs and Their Role in Catalyzing Health Solutions
• PROTACs in focus: Navigating the complexities of preclinical development
• Protein Biomarkers: The Correlation Between Proteins, Health Conditions and Exogenous Products
• Protein Science Platform
• Proteolysis Targeting Chimera
• Proteolysis Targeting Chimeras (PROTACs) Bioanalysis
• Psoriasis: Pathogenesis, Treatment, and Evolving Disease Models
• Pulmonary Disease Platform
• Q&A: How Preclinical Toxicology Contributes to Successful IND Applications
• QWBA and Mass Balance Studies
• R&D Strategies for T Cell Engager Drugs
• Radionuclide Drug Conjugates in Anticancer Treatment
• Rapid EMSA: A New Method of Testing PPB in Oligonucleotides
• Regulatory Frameworks for Central Nervous System Safety Assessment: Bridging Traditional Methods and New Modalities
• Regulatory Pathways: IND Requirement Variations Between U.S. FDA, OECD and NMPA
• Regulatory-Compliant Genetic Toxicology Assessment for Tides
• Repeat Dose Toxicity: 3 Possible Timeframes for Your IND-Enabling Studies
• Reproductive Toxicology & the EPA’s Tiered Testing System
• Respiratory Medications
• Revolutionising Eye Care: The Potential of Antisense Oligonucleotides
• RNA Horizons 2025 Therapeutics Symposium
• SABPA - The 10th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum
• Safety Assessment Services
• Safety First: How Preclinical Toxicology Shapes ASO Therapies for Rare Diseases
• Safety Pharmacology in Focus: Targeted Testing for Smarter INDs
• Science KoffiePauze
• Screening Strategies for Molecular Glue Discovery
• Semaglutide in Substance Use Disorders: Addiction Models
• Sensitive LC-MS/MS Method for Cationic Ligand-Conjugated siRNA Therapeutics
• Sensitivity of Latin Square and Ascending Dose Design for Cardiovascular Safety Pharmacology Studies in Telemetry Implanted Dogs
• SerenTPDy 2026
• Sharper, Faster, Smarter: The Mass Spectrometry Advantage in Bioanalytical Testing
• Short-Term Mouse Model to Accelerate SLE Drug Discovery
• Shortened Cardio-Metabolic Mouse Model of HFpEF
• Simoa Joint Laboratory Delivering Greater Speed, Sensitivity and Customization in Biomarker Validation
• Simultaneous In Vitro Profiling of Anticancer Efficacy and Toxicity
• SITC
• Six Ways Developers Can Address Ocular Safety in ADCs
• Small vs. Large Molecule Bioanalysis: 7 Key Differences
• Smart Strategies of ADME-PK for Large Molecules
• Smarter DMPK Strategies for Preclinical Oligonucleotide Development: Accelerate Progress & Enhance Safety
• SMR Radiopharmaceuticals
• Solving the Complexities of T Cell Engager Development
• SOT 64th Annual Meeting & ToxExpo
• SOT 65th Annual Meeting and ToxExpo
• Spatial Omics
• Spontaneous Lesions Associated with Test Article-Unrelated Deaths in Repeated Dose Mouse Studies
• Spontaneous Ocular Lesions Observed in Laboratory Animals
• Stability Testing for Drug Products: Ensuring Safety, Efficacy & Regulatory Compliance
• Stanford Drug Discovery Symposium 2026
• Statistical Power Analysis of Standard Cardiovascular Safety Pharmacology Studies in Telemetry Implanted Dogs and Nonhuman Primates
• Strategic Insights for Advancing PROTACs Toward IND Submission
• Strategies and Case Studies of JAK-STAT Targeted Therapies
• Strategies for Enhancing Oral Drug Bioavailability Inter Individual Variability and Manual Control of Gastric pH in Fasting Monkeys
• Streamlining HPAPI development: How to manage highly potent APIs through a preclinical testing process
• Stress Model for Antidepressant Drug Discovery
• Striking the Right Balance: Linker Design in ADC Cancer Therapies
• STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
• Substrate and System-Dependent Activation of CYP2B6
• Superlab Geneva Demo Day
• Supporting Discovery of mRNA Drugs
• Swiss Biotech Day
• Swiss Biotech Days 2026
• Synthetic-Lethality Screening with PARP1 inhibition
• T-Cell Engagers: Integrated Workflow to Advance TCE Candidates
• Tackling the CNS Drug Challenges with DMPK Toolkit
• Tailored Treatment: Biomarkers and the Path to Precision Medicine Based on a ‘Fit-for Purpose’ Strategy
• Target to Patient 2
• Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR
• Targeting ER Mutations and Drug Resistance
• Targeting the Untargetable: How Oligonucleotide Drugs Address Undruggable Proteins
• The 2nd BioCentury Grand Rounds Europe Conference
• The 4 Most Promising Therapeutic Applications for Peptide Drug Development
• The Advantages of LC-MS/MS in Optimizing ADC Bioassays
• The BAMA MINIPIG in Toxicology
• The Bioanalytical Challenges of In Vivo CAR-T Therapy Development
• The critical bioanalytical strategies unlocking the potential of LNP-mRNA
• The Crucial Role of Biomarkers in the Precision Medicine Revolution
• The Essential Role of Biomarkers in Modern Medicine: From Disease Diagnosis to Treatment Optimization
• The future of CNS drug development: signs of real progress
• The Future of Precision Medicine: How Bioanalysis is Transforming Personalized Healthcare
• The Future of Swedish & Danish Life Science
• The Importance of Early and Comprehensive Genetic Toxicology Testing
• The Inherent Challenges of Antibody-Drug Conjugate (ADC) Bioanalysis
• The Lab of the Future Congress Europe
• The Liver Meeting (AASLD)
• The Many DMPK Challenges of Cancer Treatment ADCs
• The Next Frontier in Oncology Discovery
• The opportunities and challenges inherent in using protein biomarkers for new drug development
• The oral exposure challenge in PROTACs: What drug developers need to solve early
• The Role and Challenges of Plasma Protein Binding in Oligonucleotide Drug Development
• The role of bioanalysis as the foundation of precision medicine
• The Strategies and Methods of in-vitro ADME Characterizations of ADCs
• The Strategy for UGT Enzyme Phenotyping
• The transition to ICH M10 and its impact on global submissions
• The Vital Role Of Toxicity Studies In Evaluating New Drugs
• Therapeutic Frontiers in Medicine: Mechanisms and Modalities
• Therapeutics for Alzheimer’s Using Antidiabetic Drugs
• Three Essential Methods for Pharmaceutical Phototoxicity Assessment
• Three Strategies to Address Development Challenges for Next-Generation Peptide Therapeutics
• Three Tips for Addressing the Complex Toxicity of ADCs
• TIDES Europe
• TIDES USA 2026
• Topical and Transdermal Drugs
• TOX Large Molecule Drug Development
• Toxicology Studies in Drug Development: What Programs Often Underestimate
• Transdermal Drug Delivery: Enhancing Permeability and In Vivo Translation
• Transforming Drug Development: How Smart Compound Management Safeguards Integrity and Boosts Efficiency
• Transforming Toxicology Scheduling
• Tumor Cell Panel | Screening Services
• UK Biotech Day
• Understanding the Sensitivity and Accuracy of FOB Tests for CNS and non-CNS Targeted Compounds
• Understanding the toxicology endpoints that matter in ADC development
• Unleashing the Power of Spectral Shift Technology
• Unlocking Drug Insights with Cutting-Edge Molecular Imaging Solutions
• Unlocking PROTACs’ Potential: Overcoming Development Challenges
• Unlocking the Potential: Navigating Non-Clinical Programs for Biotherapeutics
• Unlocking the secrets of cellular immunogenicity: A deep dive in ELISpot assays
• Unveiling Mechanisms of MRTX1133 Resistance
• Using In Vitro–In Vivo Extrapolation to Predict Human Clearance
• Utilizing Monoclonal Antibodies to Regulate Checkpoint Proteins & Boost Immune Response
• Validating Flow Cytometry-Based Micronucleus Assays in Alternative Species
• Validation of Fluorescence In Situ Hybridization Method in Mouse - With a Novel Staining Strategy
• Validation of the Flow Cytometry Based Pig-a Gene Mutation Assay in Rats
• Vienna UP - Startup Festival
• Webinar: Target Deconvolution and Tractability Assessment
• What Are GLP Toxicology Studies and Why Are They Required?
• What Are Metabolite Profiling & Identification Studies?
• What Is Bioanalytical Method Validation? A Guide to Regulatory Expectations
• What Is Bioanalytical Testing & Method Validation?
• What Is IND-Enabling Testing & What Does It Include?
• What Is Integrated Drug Discovery and Development? From Target Biology to Candidate Selection
• What Is IVIVE? 7 FAQs About In Vitro-In Vivo Extrapolation
• What Is Large Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
• What Is MTD in Drug Development, and Why It’s More Than a Number
• What Is Small Molecule Preclinical Testing? Overview, Objectives, and Key Test Methods
• What It Takes to Optimize Analytical Strategies for ADC Development
• What Toxicity Data Is Needed Before First-In-Human (FIH) Trials?
• When to Start Subchronic & Chronic Toxicology Studies
• Why are GLP Toxicology Studies Important?
• Why Half-Life Extension Isn’t Enough: A 4-Step ADME Strategy for Peptide IND Readiness
• Why Metabolite Identification Is a Regulatory Decision Point, Not Just a DMPK Exercise
• Why Non-GLP Studies Matter in Preclinical Drug Development
• Why Traditional ADME Often Fails for PROTACs
• Winning the drug development relay
• Wishing You a Joyful Holiday Season
• Wishing You a Joyful Holiday Season
• Women In TPD Networking Event Sponsorship
• World ADC
• World ADC San Diego
• WRIB
• WuXi AppTec & Quanterix Simoa Joint Lab Opening Ceremony
• WuXi AppTec Awarded Supplier Recognition Award for Outstanding Performance
• WuXi AppTec Launches R&D Center for Large Animal PK & Non-GLP Bioanalytical Research Services
• WuXi AppTec Launches Research Book Decoding DMPK Frontiers for Novel Therapeutics
• WuXi AppTec Science Forum - Barcelona, Spain
• WuXi AppTec Science Forum - Stockholm, Sweden
• WuXi AppTec Science Forum – San Francisco, California
• WuXi AppTec Spring Science Forum
• WuXi Biology HTS Platform 2.0 Launch
• WuXi Biology Launches FREE DELopen Gen5 Kit with Dual-Library Power
• WuXi Biology Launches PeptideDEL 2.0
• WuXi Global Forum 2026
• XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026)
• Yale Innovation Summit 2026
• York and North Yorkshire Life Sciences Forum
• α-Synuclein-Based Animal Models of Parkinson’s Disease